tbuckley/cabot-search huggingface dataset:
JAMA Psychiatry
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Kevin Brown, Amanda Ehrhardt, Iris Lo, M Newman, Suzanne Walker, Connie Manno, Sara Billings, Timothy Gray, Paul Ruich, Sam Wilder, Catherine Alden, Stephanie Beckmeyer, Jane Calayag, Jan Clavey, Mary Coerver-Connolly, Paula Glitman, Laura King, Regina Lilly, Joseph Mills, Brandy Patton, Thressa Smith, Donna Thordsen, Aggie Zarkadas, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Williams, Fanny Brown, Anna Bukowski, Lenette Gardner-Gullens, Tosca Hall, Erin Kato, Peter Kim, Rachell Lozano, Caroline Sietmann, Angelia Waltower, Michael Berkwits, Eric Butkus, Michelle Kurzynski, Emily Ling, Jesse Mcquarters, Daniel Morrow, Daniella Peting, Reuben Rios, Carrie Butt, Mary Ferkaluk, Karen Bucher, Andy Rekito, Nick Reback, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Deanna Bellandi, Jim Periodical, Thomas Easley, Brian Shields, Karen Adams-Taylor, Paul Gee, Monica Smith, Jeff Ery, J Bonistalli, Kathy Russell, Mirna Monal, Stacey Mchugh, Marketing Thornbury, Tricia Classifi, Thalia Moss, Tony Ralenkotter, Saskia Bolore, Gretchen Linder, Brian Mccartney, Christine Hearne, Natasha Staff, David Baum, Morgan Osgood, Ron Thomas, Rick Bell, Elizabeth Solaro, Sara Zimmerman, Geoff Rey, Fergus Clare, Lindsay Dawson, Ellen Gibson, Mustafa Ishaq, Peter Litton, Craig Mccaff Rey, Michael Mcgraw, Regina Nisengolts, Jon Perkins, Daniel Pickhardt, Romando Rossini, Sarah Subramanian, Stacy Business, Analyst Sirisha, Alluri Staff, Millette Jackson-Bates, Tom Miller, Karl Elvin, Nancy Essex, Jaye Mize, Sean O'donnell, Sue Managers, David Antos, Anthony Bautista, Chris Borden, Debbie Camp, Jennifer Carney, Lydia Cruz, Scott Curl, Diane Darnell, Jordynn Farrar, Allison Hughes, Colleen Kelly, Chris Meyer, Annemarie Neff, J Neff, Sean Ohlson, Phil O'leary, Bill Pedone, Susan Price, Binita Shah, Erin Spencer, Denise Steinhauser, Joe Advertising, Production Services, Ahmed Avendano, Kim Boler, Rhonda Brown, Fin Carter, Michael Deegan, Daniel Degroot, Euwanaha Joiner-Smith, Joshua Lane, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Ronna Hewitt, Mary Sieck, Geneine Someren, Jamaal Vargas, New Media, Gail Barrett, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Maleeka Holden, Teri Hutchison, Joshua Lampinen, Nathan Mitre, Patricia Panek, Marla Seidell, La Son, Diggs Sledge, Julian Graphics, Joe Amft, James Collver, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Carla Benton, Carol Farrell, Daniel James, Judith Literskis, Teresa Omiotek, Michael Ryder, James Madara, Bernard Hengesbaugh, Sara Dibari, Martin Paulus, Helen Simpson, New York, John Torous, Helena Chmura Kraemer, Palo Alto, Howard Bauchner
Journal: JAMA Psychiatry (2018)
The Coronary Drug Project
Journal: Circulation (1973)

The Coronary Drug Project (CDP) is a nationwide collaborative clinical trial sponsored by the National Heart and Lung Institute (NHLI). The primary objective is to evaluate the efficacy of several lipid influencing drugs in the long-term therapy of coronary heart disease in men of ages 30 through 64 with ECG evidence of previous myocardial infarction. The following six treatment regimens were included for study in the CDP: Equine estrogens 2.5 mg per day and 5.0 mg per day; clofibrate 1.8 g per day; dextrothyroxine 6.0 mg per day; nicotinic acid 3.0 g per day; and lactose placebo. There are 53 clinics participating in the CDP along with a Coordinating Center, Central Laboratory, ECG Reading Center, Drug Procurement and Distribution Center, and NHLI Medical Liaison Office. A total of 8341 patients were enrolled. All patients were randomly assigned to one of the six treatment groups in a double blind fashion and are being followed for a minimum of five years. The primary response variable in the CDP is total mortality; other major response variables include cause-specific mortality and various non-fatal cardiovascular events such as recurrent myocardial infarction, acute coronary insufficiency, and others. The CDP data are reviewed periodically by a Data and Safety Monitoring Committee for evidence of adverse and beneficial treatment effects. A detailed description of the study population with respect to demographic, clinical, biochemical, electrocardiographic, and other characteristics at baseline is given. In addition, some interrelationships among these baseline characteristics are presented.
Œuvres de Pasteur.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adoption.
Journal: BMJ (1968)

Facial Thermography: Found to be of value in preliminary investigation of patients with occlu- sive cerebrovascular disease.Severe carotid stenosis or occlusion detectable (p.521).Acute Epiglottitis: Rapid recognition and prompt treatment effected a cure in three out of four children with this rare fulminating infec- tion (p.524).Sticky Eye: TRIC agent was cause in 18% of babies investigated.Even a minor degree of infection could lead to permanent conjunctival and corneal scarring (p.527).Tuberculin Testing: Malnourished children have impaired sensitivity to tuberculin, and a higher dose may be needed to elicit a positive response (p.529).Prophylaxis of Migraine: Double blind trial of flumedroxone showed it to be of no benefit in men and none in women without history of men- strual exacerbation of migraine.Polymenorrhagia was the commonest side-effect observed (p. 531).Autoimmune Haemolytic Anaemia: Developed in three patients taking mefenamic acid.All three recovered when the drug was withdrawn (p.534).Case Reports: Intramural rupture of the oeso- phagus (p.536); Right atrial myxoma (p.537).
Constitutional Nonhematological Changes in Thalassemia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oral contraceptives and cervical cancer
Authors: D. D. Celentano
Journal: JAMA (1988)

<h3>To the Editor.</h3> —Irwin et al<sup>1</sup>recently reported that women who used oral contraceptives had no increased risk of invasive cervical cancer compared with women who had never used oral contraceptives in a case-control study in Costa Rica. We recently concluded a case-control investigation of invasive cervical cancer in Maryland,<sup>2</sup>which demonstrates that oral contraceptive use is<i>protective</i>against invasive disease (relative risk, 0.48; 95% confidence interval, 0.22 to 0.95). We conclude that rather than there being a biologically plausible association between oral contraceptives and invasive cervical cancer, the protective effect reflects increased screening among those seeking contraceptives, as others have suggested.<sup>3,4</sup>Further, our data demonstrate that lifetime use of any type of contraceptive leads to protection from invasive disease (relative risk, 0.38; 95% confidence interval, 0.20 to 0.72), with diaphragm use (relative risk, 0.29; 95% confidence interval, 0.12 to 0.67) and vaginal spermicides (relative risk, 0.28;
Histological characteristics of primary biliary cholangitis with an incomplete response to ursodeoxycholic acid
Authors: Kenichi Harada, Yuko Kakuda, Atsushi Tanaka, Masanori Abe, Tadashi Namisaki, Shinji Shimoda, Mikio Zeniya, Akio Ido, Hitoshi Yoshiji, Hiromasa Ohira, Atsushi Umeda, Yuki Kamiya, Yukari Higashine, Seiichiro Hojo, Toshio Imai, Tetsu Kawano, Hirohito Tsubouchi, Yasuni Nakanuma
Journal: Journal of Hepatology (2020)
UROLOGY AND THE GENERAL PRACTITIONER
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE ATLANTIC CITY SESSION
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Toxoplasmosis in patients receiving immunosuppressive therapy
Authors: S. N. Cohen
Journal: JAMA (1970)

Lethal, disseminated toxoplasmosis occurred in two patients, both of whom demonstrated severe central nervous system involvement. One patient, reported to have varicella zoster, was receiving immunosuppressive therapy following renal homotransplantation and is the third known patient to be reported with this infectious complication. The other patient was receiving steroids for severe marrow impairment due to a lymphoproliferative disorder, and had pathologic findings suggesting activation of latent disease.
Die Praxis der Nierenkrankheiten
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Prevention of atherosclerotic complications: controlled trial of ketanserin
Journal: BMJ (1989)

TABLE iII-Relative risks ofaortic calcification in women with natural menopause and women who had had bilateral oophorectomy according to number ofyears after menopause Natural menopause Bilateral oophorectomy No of years No with 95% No with 95% after menopause aortic calcification Relative risk* Confidence interval aortic calcification Relative risk Confidence interval
TO HAVE BEEN OR NOT TO HAVE BEEN
Journal: JAMA (1964)

Why are medical journals often dull? Among the important reasons are these: Doctors use the passive voice in their writing; they compose long complicated sentences. We say, "When I saw the patient, he had a rash," but we write, "When the patient was examined, a rash was observed." The first statement is clearer. Misuse of words is also common and insidious. Authors frequently report that a group of cases is comprised of 12 males and 7 females, when they mean that a group of patients is composed of 12 men and 7 women. Unfortunately, generations of medical writers have been tutored, deliberately or by precept, in the techniques of tortured prose, which includes, it should be noted, not only passivity and prolixity, but also sundry vices such as the utilization of polysyllabic structuralizations on a preferential basis, the use of an elongated verbalization instead of a short word, and even
PETER LUDVIG PANUM (1820-1885) DANISH EPIDEMIOLOGIST AND PHYSIOLOGIST
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In This Issue
Journal: Circulation Research (2011)

Plakoglobin and Adipogenesis in ARVC (p 1342) Too much plakoglobin protein in the nuclei of heart cells turns them into fat cells and causes arrhythmia, report Lombardi et al.Arrhythmogenic right ventricular cardiomyopathy (ARVC) is most commonly caused by mutations to genes encoding desmosome proteins, such as plakoglobin (PG).ARVC-causing mutations in PG are known to release the protein from intercellular junctions and drive its accumulation in the nucleus where it suppresses canonical Wnt signaling.To determine whether nuclear accumulation was essential for the pathogenesis of ARVC, Lombardi and colleagues made transgenic mice that overexpressed mutant or wild-type PG in the heart.They found that both proteins accumulated in the nucleus (exclusively, in the case of mutant PG), that the mice suffered arrhythmias, and that their hearts contained large numbers of fat cells (adipocytes)-a characteristic feature of ARVC.Indeed, cardiac progenitor cells isolated from the mice could spontaneously develop into adipocytes in culture.These cells also showed suppression of Wnt signaling.Treating the cells with a drug called BIO restored Wnt signaling and reversed the proadipogenic phenotype.Although the results might not be applicable to other causes of ARVC, they do suggest that those cases caused by mutant PG might benefit from a heartdirected reactivation of canonical Wnt signaling.
<i>Announcement</i>: World Stroke Day — October 29, 2016
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

The theme of World Stroke Day 2016 is "Face the Facts: Stroke is Treatable," highlighting that lives can improve with better awareness, action, and access.Stroke is a leading cause of disability and the second leading cause of death worldwide (1,2).In the United States, one person dies every 4 minutes from stroke, and up to 30% of stroke survivors are permanently disabled (3).High blood pressure is a leading risk factor for stroke (3).This year's World Stroke Day campaign aims to raise awareness that stroke is a medical emergency and should be immediately treated.Stroke is a complex medical condition, but there are ways to reduce its complications.Recognizing the signs of stroke and acting FAST (face drooping, arm weakness, speech difficulty, time to call 9-1-1), promoting awareness of specialized stroke units, and providing rapid access to proven treatments (e.g., thrombolytic drugs) improve the chances for recovery.The campaign encourages everyone, including health care professionals, to push for improved stroke care.Physicians and nurses can encourage more education about stroke among hospital staff members, and emphasize the benefits of specialized stroke units, which increase the chances of a patient having a good outcome after a stroke (4).Approximately 80% of strokes are preventable.Controlling blood pressure and cholesterol levels, and living a healthy lifestyle (e.g., exercising regularly, eating more fruits, vegetables, and foods low in sodium, and avoiding smoking) can reduce a person's chance of having a stroke.CDC supports several public health measures that address stroke, including the Paul Coverdell National Acute Stroke Program (PCNASP) and the Million Hearts initiative.The PCNASP funds nine state health departments that measure, track, and improve the quality of stroke care.Million Hearts, coled by CDC and the Centers for Medicare & Medicaid Services, aims to prevent 1 million heart attacks and strokes by 2017.
Medico-Chirurgical Transactions.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Predicting the Risk of Tumor Occurrence under the Effect of Small Doses of Carcinogens
Authors: N. Ya. Yanysheva, Yu. G. Antomonov
Journal: Environmental Health Perspectives (1976)

Basic methodological approaches were formulated for determining the permissible levels of carcinogens in man's environment on the basis of current experimental oncological data dealing with the interaction of the organism and carcinogenic compounds. The tumor is proposed as a specific index of the harmfulness criterion of carcinogenic action. Under these conditions, both the frequency and the development time of tumors must be considered. Results are given of an experimental study of the carcinogenic activity of various doses of benz[a]pyrene (0.005, 0.02, 0.1, 0.5, and 2.5 mg) on rats by using a tenfold intratracheal administration. On the basis of mathematical models of the obtained dose-time-effect relationship, the risk of cancer occurrence due to small carcinogen doses is predicted. Small doses were not tested in the experiment. On the basis of the data obtained in the experiment, a maximally permissible concentration of benz a pyrene in the ambient air can be determined. A benz[a]pyrene dose of 0.02 mg is recommended as the basis of the calculation. The effect of this dose is shown at time periods longer than the limits of human life.
Table of Contents
Authors: Christina Wyatt, Tilman Drueke, Wai Cheung, Sheng Hao, Robert Mak, Robert Spurney, Nicholas Selby, Rachel Lennon, Darren Roberts, Tom Lea-Henry, Johan De, Colin Baigent, William Herrington, Josef Coresh, Martin Landray, Adeera Levin, Vlado Perkovic, Marc Pfeffer, Peter Rossing, Michael Walsh, Christoph Wanner, David Wheeler, Wolfgang Winkelmayer, John Mcmurray
Journal: Kidney International (2017)